TB 500

Price range: $49 through $55

5MG, 10MG

TB-500 is dosed at 500 mcg–1 mg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.

In stock   |   ≥99% catalog purity

SKU: N/A Category:

Description

Product specification

Analytical Profile

Catalog data is presented for material identification and laboratory planning. Batch-specific documentation governs the supplied vial.

RESEARCH NAME TB-500 · Ac-LKKTETQ
FORMAT Lyophilised powder · 5 mg vial
MOLECULAR FORMULA C209H322N54O64
MOLECULAR MASS 889.0 g/mol
CAS REGISTRY 885340-08-9
ANALYTICAL IDENTITY HPLC + LC–MS
CATALOG CONDITION Sealed · dry · light-protected · −20°C

PROTOCOL LITERACY

Reconstitution Sequence

This source-derived sequence assumes a 10 mg vial and a final reference volume of 1.0 mL. The supplied product documentation remains the controlling instruction.

01

Metabolic

Prepare 1.0 mL of bacteriostatic water with sterile equipment.

02

INTRODUCE SLOWLY

Direct the liquid toward the inside wall of the vial to limit foaming.

03

DISSOLVE GENTLY

Roll or swirl with care until the material is dissolved; do not shake.

04

LABEL AND PROTECT

Record the preparation date and keep the vial protected from light.

05

COLD STORAGE

Refrigerate at 2-8°C and use within the four-week reference window.

UNRECONSTITUTED MATERIAL

-20°C

Keep frozen, dry, sealed, and protected from direct light. Minimise exposure to moisture.

After reconstitution

2-8°C

Keep refrigerated and light-protected. Do not freeze and use within 28 days.

Handling principle

DO NOT FREEZE

Allow the vial to reach room temperature before opening to reduce condensation. Do not freeze the reconstituted solution.

PROTOCOL LITERACY

TB 500 DOSAGE CHART

A designed reference covering concentration, weekly schedule models, reconstitution, supply planning, storage, mechanism, study observations, and administration context. It is educational material—not an individualized regimen.

VIAL CONTENT

1.0 MG

+

REFERENCE DILUENT

1.0 MG

=

STOCK CONCENTRATION

1.0 MG/ML

U-100 SCALE

1 Unit = 0.01 ml 100 mcg

01

GRADUAL 8MG MODEL

02

12 MG TRIAL CONTEXT

EDUCATIONAL REFERENCE

GRADUAL DAILY MODEL

STUDY INTERVAL STAGE WEEKLY DOSE U-100 REFERENCE SOLUTION VOLUME
01 WEEKS 1–2
INITIATION 500 mcg 30 UNITS 0.30 ML
02 WEEKS 5-8
ESCALATION 01 600 mcg 36 UNITS 0.36 ML
03 WEEKS 9-12
INITIATION 750 mcg 45 UNITS 0.45 ML
04 WEEKS 9–12
UPPER REFERENCE 1000 mcg 60 UNITS 0.60 ML

01

REFERENCE ASSUMPTIONS

Every unit and volume value shown assumes a 10 mg vial prepared to a total reference volume of 1.0 mL.

02

MATERIAL BOUNDARY

This table does not provide preparation or administration instructions.

03

PROTOCOL CONTROL

Trial documentation and qualified clinical oversight—not this chart—must govern all dosing decisions.

Product Enquiry

Have a question about this product? Send us your enquiry and our team will get back to you shortly.

Enquire Product